Amidst all of the glowing reports about immunotherapy for lung and many other cancers, it would be understandable for patients and physicians to be tempted to rush toward prioritizing immunotherapy as the first treatment strategy to pursue. In fact ...
Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment for patients with ALK or ROS1 rearrangements.
Heterogeneity in EGFR Mutations: Explaining a "Mixed Response" to EGFR TKIs in Patients with a Reported Mutation
One of the questions that comes up fairly frequently is what to make of a "mixed response" to systemic therapy: after several weeks or months of treatment, a scan shows some areas of known disease shrinking, but others are growing. Why might this happen? What does it mean? And what should it lead us to do?